The money will help Cala Health increase patient access and scale up innovation efforts, allowing the company to make devices for more conditions. Currently, the company’s Cala Trio device is used to treat essential tremor, a common neurological disorder that causes involuntary shaking.
“At Ascension Ventures, we invest in companies that are committed to changing the paradigm of care,” John Kuelper, Ascension Ventures’ senior managing director and head of healthcare technology investing, said in a Nov. 16 news release. “Cala Health is changing the standard of care by harnessing electricity as a therapy. The company is at the forefront of massive growth in bioelectronic medicine.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.